ArticleChest2010
Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease.
Article in Chest, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 85 citations in OpenAlex.
- Effectiveness of Virtual vs In-Person Inhaler Education for Hospitalized Patients With Obstructive Lung Disease: A Randomized Clinical Trial.JAMA network open · 2020Trial
- An Age-Friendly Approach to Caring for Chronic Lung Disease in the Ambulatory Setting.Respirology (Carlton, Vic.) · 2026Review
- Association between Difficulty Affording Medications and Outcomes in Chronic Obstructive Pulmonary Disease.Annals of the American Thoracic Society · 2025Article
- Out-of-Pocket Prescription Drug Savings for Medicare Beneficiaries with Asthma and COPD Under the Inflation Reduction Act.Journal of general internal medicine · 2025Article
- Out-of-Pocket Savings Under the Inhaler Price Cap.JAMA internal medicine · 2025Article
- Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions.The Journal of allergy and clinical immunology · 2025Article
- Access to Treatment for Chronic Obstructive Pulmonary Disease in the Americas: A Call for Action. A Joint Perspective from the Brazilian Thoracic Society, Canadian Thoracic Society, Latin American Thoracic Society, and the American Thoracic Society.Annals of the American Thoracic Society · 2024Article
- Downstream Effects of Market Changes on Inhalers: Impacts on Individuals With Chronic Lung Disease.Respiratory care · 2024Review
- Real-World Use of Inhaled COPD Medications: the Good, the Bad, the Ugly.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Cost-related medication nonadherence in adults with COPD in the United States 2013-2020.BMC public health · 2024Article
- Pharmacoequity in Allergy-Immunology: Disparities in Access to Medications for Allergic Diseases and Proposed Solutions in the United States and Globally.The journal of allergy and clinical immunology. In practice · 2024Review
- Breathe easy: inhalational therapy for feline inflammatory airway disease.Journal of feline medicine and surgery · 2023Review
- Associations of self-reported chronic obstructive pulmonary disease with indicators of economic instability and stress - 16 states, 2017.Chronic illness · 2023Article
- Mechanistic modeling of generic orally inhaled drug products: A workshop summary report.CPT: pharmacometrics & systems pharmacology · 2023Review
- Prescribing Patterns for Long-Acting Inhaled Bronchodilators Among Rural Adults With Chronic Obstructive Pulmonary Disease.Journal of clinical medicine research · 2022Article
- Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986-2020.Health affairs (Project Hope) · 2022Article
- Understanding barriers to and strategies for medication adherence in COPD: a qualitative study.BMC pulmonary medicine · 2022Article
- Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA.Therapeutic innovation & regulatory science · 2022Article
- What can be done to impact respiratory inhaler misuse: exploring the problem, reasons, and solutions.Expert review of respiratory medicine · 2020Review
- Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.Pharmaceutical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundChronic pulmonary diseases (CPDs) such as asthma and COPD are associated with particularly high rates of cost-related medication nonadherence (CRN), but the degree to which inhaler costs contribute to this is not known. Here, we examine the relationship between inhaler-specific out-of-pocket costs and CRN in CPD.
methodsUsing data obtained in 2006 in a national stratified random sample (N = 16,072) of community-dwelling Medicare beneficiaries aged >or= 65 years, we used logistic regression to examine the relationship between inhaled medications, various types of out-of-pocket costs, and CRN in persons with CPD.
resultsThe prevalence of CRN in Medicare recipients with CPD using inhalers was 31%. In multivariate models, the odds that respondents with CPD using inhalers would report CRN was 1.43 (95% CI, 1.21-1.69) compared with respondents without CPD who were not using inhalers. Adjustment for out-of-pocket inhaler costs-but not adjustment for total medication costs or non-inhaler costs-eliminated this excess risk of CRN (OR, 0.95; 95% CI, 0.71-1.28). Patients paying > $20 per month for inhalers were at significantly higher risk for CRN compared with those who had no out-of-pocket inhaler costs.
conclusionsIndividuals with CPD and high out-of-pocket inhaler costs are at increased risk for CRN relative to individuals on other medications. Physicians should be aware that inhalers can pose a particularly high risk of medication nonadherence for some patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.